The case for & against
Bull & Bear analysis
Rhythm Pharmaceuticals, Inc. (NASDAQ: RYTM) is a biotechnology company specializing in the development of innovative therapies targeting rare genetic disorders related to obesity, including Bardet-Biedl Syndrome (BBS) and Acquired Hypothalamic Obesity (HO). With a promising pipeline, particularly its lead product setmelanotide, Rhythm is positioned as a potentially leading player in addressing significant unmet medical needs in these niche therapeutic landscapes. The company displays a strong focus on the development of solutions that integrate hormonal and metabolic findings, solidifying its role within the broader healthcare paradigm of metabolic disease management.
Bull says
- ↑Q1 2026 revenue hit $60 M, up 5% sequential in BBS sales
- ↑Gross margin ~84% for U.S. sales indicates strong cost control
- ↑Analyst consensus 'Moderate Buy' with $133.13 target (~16.6% upside)
- ↑>150 setmelanotide start forms show early adoption momentum
- ↑High institutional ownership and positive momentum/growth factors
- ↑Cash position $341 M supports operations for ~24 months
Bear says
- ↓Negative earnings yield raises valuation concerns
- ↓Profitability remains negative, questioning sustainable profits
- ↓2026 non-GAAP OPEX guided at $385–415 M, straining margins
- ↓Elevated volatility points to potential erratic price swings
- ↓Reimbursement delays risk slowing HO market penetration
- ↓Weak book-to-price hints at intrinsic value erosion
Investment themes with RYTM
Genetic and drug innovations driving medical breakthroughs
Products and services targeting weight management
Earnings Call · Q1 2026 · Mgmt. Guidance
Transcript signals
Bull points
- Rhythm is well capitalized and off to a strong start of what promises to be a transformational 2026.
- We had a solid first quarter of 2026 with $60.1 million in global net revenues from sales of MCIVRI, which represents 5% sequential growth over Q4 2025.
- Globally, we saw continued growth in patients on reimbursed therapy with an 8% increase over the prior quarter, driven primarily by BBS.
Bear points
- GAAP EPS for the first quarter of 2026 was a net loss per basic and diluted share of 83 cents, including 2 cents per share from accrued dividends on convertible preferred stock of $1.1 million.
- the primary gating factors could be two pieces. The primary one is the pace and the schedule just in terms of those patients coming in to have that dialogue around MCFRI. So that is, you know, really preplanned just in terms of what that normal visit may look like for that patient. I think the other factor is, as we also continued with our education with ACPs, there were some patients that may have come top of mind or had already been diagnosed, but through our education, they also had several aha moments just in terms of other patients that they suspected may also have AHO.